ペグセタコプラン（APL-2）新薬の考察と市場予測（2032年）

当レポートでは、ペグセタコプラン（APL-2）新薬の主要7市場（米国・ドイツ・フランス・イタリア・スペイン・英国・日本）について調査分析し、作用機序、用法・用量、研究開発活動の考察、市場予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 筋萎縮性側索硬化症におけるペグセタコプランの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済みの治療法）

第4章 競合情勢（後期の新しい治療法）

第5章 ペグセタコプラン（APL-2）市場の評価

• 筋萎縮性側索硬化症におけるペグセタコプラン市場の見通し
• 主要7市場の分析
  • 筋萎縮性側索硬化症に対するペグセタコプラン（APL-2）の主要7市場の市場規模
• 市場の分析：国別
  • 筋萎縮性側索硬化症に対する米国のペグセタコプラン（APL-2）の市場規模
  • 筋萎縮性側索硬化症に対するドイツのペグセタコプラン（APL-2）の市場規模
  • 筋萎縮性側索硬化症に対する英国のペグセタコプラン（APL-2）の市場規模
  • 筋萎縮性側索硬化症に対する日本のペグセタコプラン（APL-2）市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1:Pegcetacoplan, Clinical Trial Description, 2022
• Table 2: Pegcetacoplan (APL-2) : General Description
• Table 3: Competitive Landscape ( Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: Pegcetacoplan (APL-2) Market Size in the 7MM, in USD million (2019-2032)
• Table 6: Pegcetacoplan (APL-2) Market Size in the US, in USD million (2019-2032)
• Table 7: Pegcetacoplan (APL-2) Market Size in Germany, in USD million (2019-2032)
• Table 8: Pegcetacoplan (APL-2) Market Size in France, in USD million (2019-2032)
• Table 9: Pegcetacoplan (APL-2) Market Size in Italy, in USD million (2019-2032)
• Table 10: Pegcetacoplan (APL-2) Market Size in Spain, in USD million (2019-2032)
• Table 11: Pegcetacoplan (APL-2) Market Size in the UK, in USD million (2019-2032)
• Table 12: Pegcetacoplan (APL-2) Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Pegcetacoplan (APL-2) Market Size in the 7MM, USD million (2019-2032)
• Figure 2: Pegcetacoplan (APL-2) Market Size in the United States, USD million (2019-2032)
• Figure 3: Pegcetacoplan (APL-2) Market Size in Germany, USD million (2019-2032)
• Figure 4: Pegcetacoplan (APL-2) Market Size in France, USD million (2019-2032)
• Figure 5: Pegcetacoplan (APL-2) Market Size in Italy, USD million (2019-2032)
• Figure 6: Pegcetacoplan (APL-2) Market Size in Spain, USD million (2019-2032)
• Figure 7: Pegcetacoplan (APL-2) Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: Pegcetacoplan (APL-2) Market Size in Japan, USD million (2019-2032)

"Pegcetacoplan (APL-2), Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about Pegcetacoplan (APL-2) for Amyotrophic Lateral Sclerosis in the 7MM. A detailed picture of the Pegcetacoplan (APL-2) for Amyotrophic Lateral Sclerosis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the Pegcetacoplan (APL-2) for Amyotrophic Lateral Sclerosis. The report provides Insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Pegcetacoplan (APL-2) market forecast, analysis for Amyotrophic Lateral Sclerosis in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Amyotrophic Lateral Sclerosis.

Drug Summary:

Pegcetacoplan (APL-2) is an investigational, C3 targeted therapy designed to regulate excessive or uncontrolled complement activation, which can lead to the onset and progression of many serious diseases. The drug is a synthetic cyclic peptide conjugated to a polyethylene glycol polymer that binds specifically to C3 and C3b. It is believed that this approach can regulate uncontrolled or excessive complement activation that occurs in several debilitating diseases, including those in hematology, ophthalmology, nephrology, and neurology.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the Pegcetacoplan (APL-2) description, mechanism of action, dosage and administration, research and development activities in Amyotrophic Lateral Sclerosis.
• Elaborated details on Pegcetacoplan (APL-2) regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Pegcetacoplan (APL-2) research and development activity in Amyotrophic Lateral Sclerosis details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Pegcetacoplan (APL-2).
• The report contains forecasted sales of Pegcetacoplan (APL-2) for Amyotrophic lateral sclerosis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Amyotrophic Lateral Sclerosis.
• The report also features the SWOT analysis with analyst views for Pegcetacoplan (APL-2) in Amyotrophic Lateral Sclerosis.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Pegcetacoplan (APL-2) Analytical Perspective by DelveInsight

• In-depth Pegcetacoplan (APL-2) Market Assessment

This report provides a detailed market assessment of Pegcetacoplan (APL-2) in Amyotrophic lateral sclerosis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

• Pegcetacoplan (APL-2) Clinical Assessment

The report provides the clinical trials information of Pegcetacoplan (APL-2) in Amyotrophic Lateral Sclerosis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Amyotrophic lateral sclerosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Pegcetacoplan (APL-2) dominance.
• Other emerging products for Amyotrophic Lateral Sclerosis are expected to give tough market competition to Pegcetacoplan (APL-2) and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Pegcetacoplan (APL-2) in Amyotrophic Lateral Sclerosis.
• Our in-depth analysis of the forecasted sales data of Pegcetacoplan (APL-2) from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Pegcetacoplan (APL-2) in Amyotrophic Lateral Sclerosis.

Key Questions

• What is the product type, route of administration and mechanism of action of Pegcetacoplan (APL-2)?
• What is the clinical trial status of the study related to Pegcetacoplan (APL-2) in Amyotrophic lateral sclerosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Pegcetacoplan (APL-2) development?
• What are the key designations that have been granted to Pegcetacoplan (APL-2) for Amyotrophic Lateral Sclerosis?
• What is the forecasted market scenario of Pegcetacoplan (APL-2) for Amyotrophic Lateral Sclerosis?
• What are the forecasted sales of Pegcetacoplan (APL-2) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Amyotrophic Lateral Sclerosis and how are they giving competition to Pegcetacoplan (APL-2) for Amyotrophic Lateral Sclerosis?
• Which are the late-stage emerging therapies under development for the treatment of Amyotrophic Lateral Sclerosis?

Table of Contents

1. Report Introduction

2. Pegcetacoplan Overview in Amyotrophic Lateral Sclerosis

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical Studies
  • 2.2.2. Clinical Trials Information
  • 2.2.3. Safety and Efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)*

5. Pegcetacoplan (APL-2) Market Assessment

• 5.1. Market Outlook of Pegcetacoplan in Amyotrophic Lateral Sclerosis
• 5.2. 7MM Market Analysis
  • 5.2.1. Market Size of Pegcetacoplan (APL-2) in the 7MM for Amyotrophic Lateral Sclerosis
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Pegcetacoplan (APL-2) in the US for Amyotrophic Lateral Sclerosis
  • 5.3.2. Market Size of Pegcetacoplan (APL-2) in Germany for Amyotrophic Lateral Sclerosis
  • 5.3.3. Market Size of Pegcetacoplan (APL-2) in France for Amyotrophic Lateral Sclerosis
  • 5.3.4. Market Size of Pegcetacoplan (APL-2) in Italy for Amyotrophic Lateral Sclerosis
  • 5.3.5. Market Size of Pegcetacoplan (APL-2) in Spain for Amyotrophic Lateral Sclerosis
  • 5.3.6. Market Size of Pegcetacoplan (APL-2) in the UK for Amyotrophic Lateral Sclerosis
  • 5.3.7. Market Size of Pegcetacoplan (APL-2) Japan for Amyotrophic Lateral Sclerosis

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options